TOFACITINIB CITRATE | A209633 | BRECKENRIDGE PHARMACEUTICAL INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Pfizer Inc. et al v. Breckenridge Pharmaceutical Inc. et al 4 patentsANDA 209633tofacitinib citrate | D. Del. | 2017-10-30 | Terminated 2018-06-06 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
No patent or exclusivity listings for this strength.
Breckenridge received FDA approval for a new tofacitinib citrate product (NDA 209633, supplement 002).
New: New record
Breckenridge received FDA approval for tofacitinib citrate (NDA 209633, strength 001).
New: New record